达巴万星对全球监测项目中耐药金黄色葡萄球菌分离株的体外活性。
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.
机构信息
Durata Therapeutics, Branford, Connecticut, USA
JMI Laboratories, North Liberty, Iowa, USA.
出版信息
Antimicrob Agents Chemother. 2015 Aug;59(8):5007-9. doi: 10.1128/AAC.00274-15. Epub 2015 May 18.
Abstract
In over a decade (2002 to 2012) of Staphylococcus aureus surveillance testing on 62,195 isolates, dalbavancin was demonstrated to be active against isolates that were either susceptible or nonsusceptible to daptomycin, linezolid, or tigecycline. Nearly all (99.8%) multidrug-resistant methicillin-resistant S. aureus isolates were inhibited by dalbavancin at ≤0.12 μg/ml (MIC50/90, 0.06/0.06 μg/ml), the current U.S. Food and Drug Administration (U.S. FDA) breakpoint. Overall, only 0.35% of the monitored S. aureus isolates had a dalbavancin MIC of either 0.25 or 0.5 μg/ml (i.e., were nonsusceptible).
摘要
在对 62195 株金黄色葡萄球菌进行了超过十年（2002 年至 2012 年）的监测检测中，达巴万星对达托霉素、利奈唑胺或替加环素敏感或耐药的分离株均表现出活性。几乎所有（99.8%）的多药耐药性耐甲氧西林金黄色葡萄球菌分离株对达巴万星的抑制浓度均≤0.12μg/ml（MIC50/90，0.06/0.06μg/ml），这是目前美国食品和药物管理局（美国 FDA）的折点。总体而言，仅监测到金黄色葡萄球菌分离株中有 0.35%的达巴万星 MIC 为 0.25 或 0.5μg/ml（即耐药）。
相似文献
1
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance Program.
Antimicrob Agents Chemother. 2015 Aug;59(8):5007-9. doi: 10.1128/AAC.00274-15. Epub 2015 May 18.
2
Activity of dalbavancin tested against Gram-positive clinical isolates causing skin and skin-structure infections in paediatric patients from US hospitals (2014-2015).
J Glob Antimicrob Resist. 2017 Dec;11:4-7. doi: 10.1016/j.jgar.2017.06.003. Epub 2017 Jul 19.
3
Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.
Clin Exp Pharmacol Physiol. 2014 Jun;41(6):437-43. doi: 10.1111/1440-1681.12195.
4
In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains.
J Antimicrob Chemother. 2017 Feb;72(2):441-443. doi: 10.1093/jac/dkw416. Epub 2016 Sep 28.
5
analysis of the minimal inhibitory concentration values of different generations of anti-methicillin-resistant antibiotics.
Indian J Med Microbiol. 2018 Jan-Mar;36(1):119-120. doi: 10.4103/ijmm.IJMM_17_136.
6
Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.
Antimicrob Agents Chemother. 2018 Feb 23;62(3). doi: 10.1128/AAC.02397-17. Print 2018 Mar.
7
In vitro activity of dalbavancin against multidrug-resistant Staphylococcus aureus and streptococci from patients with documented infections in Europe and surrounding regions (2011-2013).
Int J Antimicrob Agents. 2016 Jun;47(6):495-9. doi: 10.1016/j.ijantimicag.2016.04.009. Epub 2016 May 12.
8
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin, or vancomycin from U.S. hospitals, 2008 to 2011.
Antimicrob Agents Chemother. 2013 Jul;57(7):3178-81. doi: 10.1128/AAC.00484-13. Epub 2013 Apr 29.
9
Activities of Omadacycline and Comparator Agents against Staphylococcus aureus Isolates from a Surveillance Program Conducted in North America and Europe.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02411-16. Print 2017 Mar.
10
In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
J Microbiol Immunol Infect. 2011 Oct;44(5):346-51. doi: 10.1016/j.jmii.2011.01.037. Epub 2011 Jan 20.
引用本文的文献
1
A Narrative Review on the Role of Dalbavancin in the Treatment of Bone and Joint Infections.
Antibiotics (Basel). 2023 Sep 28;12(10):1492. doi: 10.3390/antibiotics12101492.
2
[Not Available].
Glob Reg Health Technol Assess. 2020 Nov 6;7:92-100. doi: 10.33393/grhta.2020.2138. eCollection 2020 Jan-Dec.
3
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
4
Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics.
J Antimicrob Chemother. 2021 Nov 22;76(Suppl 4):iv9-iv22. doi: 10.1093/jac/dkab351.
5
Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context.
Biomedicines. 2021 Sep 22;9(10):1288. doi: 10.3390/biomedicines9101288.
6
Dalbavancin for the Treatment of Prosthetic Joint Infections: A Narrative Review.
Antibiotics (Basel). 2021 May 31;10(6):656. doi: 10.3390/antibiotics10060656.
7
Antimicrobial resistance in methicillin-resistant to newer antimicrobial agents.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01216-19. Epub 2019 Sep 16.
8
Comparative efficacy and safety of antibiotics used to treat acute bacterial skin and skin structure infections: Results of a network meta-analysis.
PLoS One. 2017 Nov 14;12(11):e0187792. doi: 10.1371/journal.pone.0187792. eCollection 2017.
9
In vitro activity of dalbavancin and five comparator agents against common and uncommon Gram-positive organisms isolated from cancer patients.
J Antibiot (Tokyo). 2016 May;69(5):381-7. doi: 10.1038/ja.2015.120. Epub 2015 Dec 2.
10
Lipoglycopeptide Antibacterial Agents in Gram-Positive Infections: A Comparative Review.
Drugs. 2015 Dec;75(18):2073-95. doi: 10.1007/s40265-015-0505-8.
本文引用的文献
1
Once-weekly dalbavancin versus daily conventional therapy for skin infection.
N Engl J Med. 2014 Jun 5;370(23):2169-79. doi: 10.1056/NEJMoa1310480.
2
MRSA: the first half century.
J Antimicrob Chemother. 2012 Jan;67(1):4-11. doi: 10.1093/jac/dkr437. Epub 2011 Oct 18.
3
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.
Clin Microbiol Infect. 2012 Mar;18(3):268-81. doi: 10.1111/j.1469-0691.2011.03570.x. Epub 2011 Jul 27.
4
Serious infections caused by methicillin-resistant Staphylococcus aureus.
Clin Infect Dis. 2010 Sep 15;51 Suppl 2:S183-97. doi: 10.1086/653519.
5
Semisynthetic glycopeptides: chemistry, structure-activity relationships and prospects.
Farmaco. 1997 May;52(5):313-21.
6
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
J Antimicrob Chemother. 1997 Jul;40(1):135-6. doi: 10.1093/jac/40.1.135.
Zotero 插件